Raphael Pharmaceutical ready to launch RaphaWell RA supplement in US after clinical trial

Raphael Pharmaceutical Inc.

RaphaWell is a 100% natural, plant-based dietary supplement for rheumatoid arthritis symptom management.
Completed proof-of-concept clinical trial under IRB approval; pain levels reduced from 75% negative to 50% at week 8.
Morning stiffness improved from 75% participants at baseline to 41.67% at week 8.
Company intends to engage a US manufacturer to scale production; product to be sold as standalone supplement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.